Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
Total Assets
Avadel Pharmaceuticals PLC
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Total Assets
$199.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
1%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Total Assets
$10.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Total Assets
$11.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
13%
|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Total Assets
$32.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Total Assets
€646.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
2%
|
CAGR 10-Years
4%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Total Assets
€2.7m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-19%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Total Assets?
Total Assets
199.4m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Total Assets amounts to 199.4m USD.
What is Avadel Pharmaceuticals PLC's Total Assets growth rate?
Total Assets CAGR 10Y
1%
Over the last year, the Total Assets growth was 26%. The average annual Total Assets growth rates for Avadel Pharmaceuticals PLC have been 11% over the past three years , -9% over the past five years , and 1% over the past ten years .
